FDA Adverse Event Injury Summary report: N

MEDTRONIC TRANSCATHETER VALVE

MDR report key: 17695036 · Received September 6, 2023

Report

Report Number
2025587-2023-03657
Event Type
Injury
Date Received
September 6, 2023
Date of Event
March 20, 2023
Report Date
September 6, 2023
Manufacturer
MEDTRONIC HEART VALVES DIVISION
Product Code
NPT
PMA / PMN Number
P130021
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

CITATION: KODRA A, CINELLI M, ALEXANDER R, ET AL. COMPARISON OF PERIPROCEDURAL AND INTERMEDIATE-TERM OUTCOMES OF TAVI IN PATIENTS WITH EJECTION FRACTION = 20% VS. PATIENTS WITH 20% EF = 40. J CLIN MED. 2023;12(6):2390. PUBLISHED 2023 MAR 20. DOI:10.3390/JCM12062390 EARLIEST DATE OF PUBLICATION USED FOR DATE OF EVENT. MEDTRONIC PRODUCTS REFERENCED: COREVALVE (PRODUCT CODE NPT, PMA# P130021), EVOLUT R (PRODUCT CODE NPT, PMA# P130021), EVOLUT PRO (PRODUCT CODE NPT, PMA# P130021), EVOLUT PRO+ (PRODUCT CODE NPT, PMA# P130021). EARLIEST APPROVED PRODUCT USED FOR PRODUCT CODE AND PMA#. NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. WITHOUT RETURN OF THE PRODUCT, NO DEFINITIVE CONCLUSION CAN BE MADE REGARDING THE CLINICAL OBSERVATIONS. MEDTRONIC IS SUBMITTING THIS REPORT TO COMPLY WITH FDA REPORTING REGULATIONS UNDER 21 CFR PARTS 4 AND 803. THIS REPORT IS BASED UPON INFORMATION OBTAINED BY MEDTRONIC, WHICH THE COMPANY MAY NOT HAVE BEEN ABLE TO FULLY INVESTIGATE OR VERIFY PRIOR TO THE DATE THE REPORT WAS REQUIRED BY THE FDA. MEDTRONIC HAS MADE REASONABLE EFFORTS TO OBTAIN MORE COMPLETE INFORMATION AND HAS PROVIDED AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. IN PARTICULAR, THIS REPORT DOES NOT CONSTITUTE AN ADMISSION BY ANYONE THAT THE PRODUCT DESCRIBED IN THIS REPORT HAS ANY ¿DEFECTS¿ OR HAS ¿MALFUNCTIONED¿. THESE WORDS ARE INCLUDED IN THE FDA 3500A FORM AND ARE FIXED ITEMS FOR SELECTION CREATED BY THE FDA TO CATEGORIZE THE TYPE OF EVENT SOLELY FOR THE PURPOSE OF REGULATORY REPORTING. MEDTRONIC OBJECTS TO THE USE OF THESE WORDS AND OTHERS LIKE THEM BECAUSE OF THE LACK OF DEFINITION AND THE CONNOTATIONS IMPLIED BY THESE TERMS. THIS STATEMENT SHOULD BE INCLUDED WITH ANY INFORMATION OR REPORT DISCLOSED TO THE PUBLIC UNDER THE FREEDOM OF INFORMATION ACT. A GOOD FAITH EFFORT WILL BE MADE TO OBTAIN THE APPLICABLE INFORMATION RELEVANT TO THE REPORT. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 0

LITERATURE WAS REVIEWED REGARDING THE OUTCOMES OF TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) IN PATIENTS WITH SEVERELY REDUCED EJECTION FRACTION. MEDTRONIC (COREVALVE, EVOLUT R, EVOLUT PRO, AND EVOLUT PRO+) AND NON-MEDTRONIC (EDWARDS SAPIEN) TRANSCATHETER VALVE TYPES WERE USED IN THE STUDY. THE AUTHORS OBSERVED 37 DEATHS WITHIN ONE YEAR OF TAVR. NO EVIDENCE WAS PRESENTED TO SUGGEST THAT A MEDTRONIC VALVE OR ITS FUNCTION CONTRIBUTED TO ANY OF THE DEATHS. ADDITIONAL OUTCOMES THAT OCCURRED WERE DESCRIBED AS FOLLOWS: PARAVALVULAR LEAK (MODERATE TO SEVERE), STROKE, CONVERSION TO OPEN SURGERY, AORTIC VALVE RE-INTERVENTION, NEED FOR PERMANENT PACEMAKER IMPLANTATION, NEED FOR INTRA-AORTIC BALLOON PUMP SUPPORT, EMERGENCY EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT, INTRA-OPERATIVE HYPOTENSION, INTRA-OPERATIVE NEED FOR VASOPRESSOR SUPPORT, POST-OPERATIVE BLEEDING REQUIRING TRANSFUSIONS, ELEVATED MEAN AORTIC VALVE GRADIENT, AND REHOSPITALIZATION WITHIN 30 DAYS OF DISCHARGE. NO FURTHER INFORMATION PERTAINING TO MEDTRONIC PRODUCTS WAS NOTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1170773 MEDTRONIC TRANSCATHETER VALVE AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV NPT MEDTRONIC HEART VALVES DIVISION MDT-TRANS VALVE

Patients

Seq Age Sex Outcome Treatment
1 81 YR Male Hospitalization| R| L